The Week In Biopharma, May 9 – 13
Contract Research (CROs)
- Avacta Relocates Therapeutics Division to Scale Space, Imperial College White City Campus (UK)
- IllumiCare consultation app takes hassle out of connecting patients to trials (USA)
Contract Development and Manufacturing (CDMO)
- LOTTE to Purchase BMS East Syracuse NY Manufacturing Facility (USA)
- Bora Pharmaceuticals Acquires Eden Biologics (Taiwan)
- Cytiva Opening New Facility in (Switzerland)
- Brainlab Announces the Majority Acquisition of medPhoton (Germany)
- Cellipont Bioservices Expands Cell Therapy Facility (USA)
- Qosina Launches New Bioprocess Resource Center (USA)
- Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class (Switzerland)
- PCI Pharma Services Unveils Major Manufacturing Expansion (USA)
- Lubrizol Life Sciences Health Launches Apisolex (USA)
- Bachem, Lilly Enter Strategic Oligonucleotide API Pact (Switzerland/USA)
- Avantor, Cytovance Biologics Enter Plasmid DNA Development Pact (USA)
Biopharma
- FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes (USA)
- Biostage Announces $5.1 Million Financing to Advance Clinical Trial (USA)
- BMS & BridgeBio Team Up in Nearly $1B Oncology Pact (USA)
- Astex Pharmaceuticals, Inc Announces Phase 3 ASCERTAIN – Acute Myeloid Leukemia (AML) Clinical Study Result (USA)
- MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds (Israel)
- Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl (Japan)
- NeoTX Acquires InterX, Adds World Class Discovery Arm (Israel)
- Cullinan Oncology and Taiho Reunite to Co-Develop NSCLC Drug (USA/Canada)
- Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes (USA)
- Neuvivo Begins Manufacture of ALS Treatment NP001 (USA)
- Novo Nordisk, Flagship’s forward-thinking partnership aims to treat cardiometabolic, rare diseases (Denmark/USA)
- BlueWind Medical breezes into $64M series B for overactive bladder neurostim device (Israel)
- More Moma: $150M series B will push precision cancer drugs to clinic by 2024 (USA)
- Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name (USA)
- Pfizer to Acquire Biohaven Pharmaceuticals for $11.6 Billion (USA)
- Ashfield Engage Acquires PROPENSITY4 (USA)
- ALSA Ventures, Lonza Partner to Provide Biotech Support & Services (UK/Switzerland)
- selectION Inc. Advances Lead Program for Treatment of T Cell Mediated Autoimmune Diseases to Clinical Development (Germany)
- OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases (USA)
- Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression (USA/Japan)
Artificial Intelligence
- Mammogram-reading AI developer Therapixel snags €15M to expand US presence (USA)
- VeriSIM Life Announces Acquisition of Molomics Biotech (USA)
